Core Insights - Anbio Biotechnology is actively participating in three major international exhibitions to expand its global presence in human and veterinary healthcare [1][5] - The company aims to meet the increasing demand for faster, more accurate, and decentralized testing solutions through its diversified portfolio and expanding global network [2][5] - Anbio's mission focuses on reshaping diagnostics through collaboration, innovation, and accessibility, as stated by its CEO [3][5] Company Strategy - Anbio has product registrations in over 100 countries and is pursuing a global strategy of innovation, collaboration, and commercialization [5][7] - The company is seeking distribution partners, research collaborators, and strategic investors to enhance diagnostic access and co-develop market-specific solutions [6][7] Product Offerings - Anbio's diagnostic portfolio includes Fluorescence Immunoassay (FIA) Systems, Dry Chemistry Analyzers, Rapid Test Kits, Molecular Diagnostic Systems, and a Veterinary Diagnostics Suite [8] - The FIA Systems support 90 test items for rapid and quantitative detection across various clinical areas [8] - Dry Chemistry Analyzers are designed for essential biochemical testing at the point of care, ideal for decentralized settings [8] - The Molecular Diagnostic System includes LAMP-based Rapid Mdx System and real-time RT-PCR reagents, enabling faster nucleic acid detection [8] - The Veterinary Diagnostics Suite integrates various diagnostic methods to support companion animal health needs [8]
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions